^
    Back
    Association details:
    Biomarker:MET amplification
    Cancer:Gastric Cancer
    Drug:Tepmetko (tepotinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma

    Excerpt:
    ...Phase 2b: Subjects with histologically confirmed locally advanced or metastatic gastric and gastroesophageal carcinoma that have progressed after treatment with first-line fluoropyrimidine-based chemotherapy, with MET amplified (copy number gain ≥3) or MET exon 14 skipping mutation in the archival or fresh tumor tissue specimen identified in study customized targeted DNA deep sequencing (NGS by gastric cancer panel)....
    Trial ID:
    NCT05439993
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2022
    Title:

    Responses to the MET inhibitor tepotinib in gastric cancers with MET amplification or both high PD-L1 expression and an MET exon 14 skipping mutation.

    Published date:
    05/26/2022
    Excerpt:
    We assessed the antitumor activity of tepotinib in GC cell lines….Tepotinib treatment showed dose-dependent growth inhibition of c-MET-amplified SNU620, MKN45, Hs746T, SNU638 and KATO III cells with concomitant induction of apoptosis.
    DOI:
    10.1200/JCO.2022.40.16_suppl.e16037